MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

NCT04312698 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-07-28

No results posted yet for this study

Summary

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Conditions

  • Dyslipidemia Patients With Hypertension

Interventions

DRUG

D013, D326, D337

Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337

DRUG

placebo of D013, D326, D337

Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013

DRUG

D013, placebo of D326, placebo of D337

Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-29
Primary Completion
2021-06-18
Completion
2021-06-18

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312698 on ClinicalTrials.gov